高効能API(HPAPI)の世界市場2020-2026:画期的、一般

QYResearchが発行した調査報告書(QYR20AP01004)
◆英語タイトル:Global High Potency APIs (HPAPI) Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP01004
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:140
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、高効能API(HPAPI)の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、高効能API(HPAPI)のグローバル市場動向、メーカー別競争状況、種類別市場規模(画期的、一般)、用途別市場規模(腫瘍学、緑内障、ホルモン不均衡、呼吸器疾患、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・高効能API(HPAPI)の種類別市場2015-2026:画期的、一般
・高効能API(HPAPI)の用途別市場2015-2026:腫瘍学、緑内障、ホルモン不均衡、呼吸器疾患、その他
・高効能API(HPAPI)の北米市場分析
・高効能API(HPAPI)のアジア市場分析
・高効能API(HPAPI)の中南米市場分析
・高効能API(HPAPI)の中東・アフリカ市場分析
・関連企業情報:Pfizer (US)、Novartis (Switzerland)、Sanofi (France)、Roche (Switzerland)、Eli Lilly and Company (US)、Merck (US)、AbbVie (US)、Boehringer Ingelheim (Germany)、GlaxoSmithKline (UK)、RAG-Stiftung (Germany)、Bristol-Myers Squibb (US)、Teva (Israel)、Mylan (US)、AstraZeneca (UK)、Lonza (Swiss)、Ash Stevens (US)、AMRI (US)
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

HPAPI is a very effective pharmacological active ingredient.Their effects are highly specific, providing significant efficiencies even at low daily therapeutic doses.In 2019, the global High Potency APIs (HPAPI) market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of xx% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for High Potency APIs (HPAPI).
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global High Potency APIs (HPAPI) market. The analysts authoring the report have closely studied key strategies adopted by top players of the global High Potency APIs (HPAPI) market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global High Potency APIs (HPAPI) market. Readers of the report can become informed about current and future trends of the global High Potency APIs (HPAPI) market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise High Potency APIs (HPAPI) markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global High Potency APIs (HPAPI) market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global High Potency APIs (HPAPI) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global High Potency APIs (HPAPI) market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the High Potency APIs (HPAPI) market is segmented into
Innovative
Generic

Market Segment by Application, the High Potency APIs (HPAPI) market is segmented into
Oncology
Glaucoma
Hormonal Imbalance
Respiratory Disorders
Other

This report includes the following manufacturers; we can also add the other companies as you want.
Pfizer (US)
Novartis (Switzerland)
Sanofi (France)
Roche (Switzerland)
Eli Lilly and Company (US)
Merck (US)
AbbVie (US)
Boehringer Ingelheim (Germany)
GlaxoSmithKline (UK)
RAG-Stiftung (Germany)
Bristol-Myers Squibb (US)
Teva (Israel)
Mylan (US)
AstraZeneca (UK)
Lonza (Swiss)
Ash Stevens (US)
AMRI (US)

The study objectives are:
To analyze and research the global High Potency APIs (HPAPI) status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key High Potency APIs (HPAPI) manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of High Potency APIs (HPAPI) are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top High Potency APIs (HPAPI) Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global High Potency APIs (HPAPI) Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Innovative
1.3.3 Generic
1.4 Market Segment by Application
1.4.1 Global High Potency APIs (HPAPI) Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Oncology
1.4.3 Glaucoma
1.4.4 Hormonal Imbalance
1.4.5 Respiratory Disorders
1.4.6 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global High Potency APIs (HPAPI) Revenue (2015-2026)
2.1.1 Global High Potency APIs (HPAPI) Revenue (2015-2026)
2.1.2 Global High Potency APIs (HPAPI) Sales (2015-2026)
2.2 High Potency APIs (HPAPI) Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global High Potency APIs (HPAPI) Sales by Regions (2015-2020)
2.2.2 Global High Potency APIs (HPAPI) Revenue by Regions (2015-2020)
2.3 Global Top High Potency APIs (HPAPI) Regions (Countries) Ranking by Market Size
2.4 High Potency APIs (HPAPI) Industry Trends
2.4.1 High Potency APIs (HPAPI) Market Top Trends
2.4.2 Market Drivers
2.4.3 High Potency APIs (HPAPI) Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key High Potency APIs (HPAPI) Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top High Potency APIs (HPAPI) Manufacturers by Sales (2015-2020)
3.1.1 Global High Potency APIs (HPAPI) Sales by Manufacturers (2015-2020)
3.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by High Potency APIs (HPAPI) Sales in 2019
3.2 Global Top Manufacturers High Potency APIs (HPAPI) by Revenue
3.2.1 Global High Potency APIs (HPAPI) Revenue by Manufacturers (2015-2020)
3.2.2 Global High Potency APIs (HPAPI) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global High Potency APIs (HPAPI) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency APIs (HPAPI) as of 2019)
3.4 Global High Potency APIs (HPAPI) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers High Potency APIs (HPAPI) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into High Potency APIs (HPAPI) Market
3.7 Key Manufacturers High Potency APIs (HPAPI) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global High Potency APIs (HPAPI) Historic Market Review by Type (2015-2020)
4.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
4.1.3 Global High Potency APIs (HPAPI) Revenue Market Share by Type (2015-2020)
4.1.4 High Potency APIs (HPAPI) Price by Type (2015-2020)
4.1 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global High Potency APIs (HPAPI) Sales Forecast by Type (2021-2026)
4.2.3 Global High Potency APIs (HPAPI) Revenue Forecast by Type (2021-2026)
4.2.4 High Potency APIs (HPAPI) Price Forecast by Type (2021-2026)

5 Global High Potency APIs (HPAPI) Market Size by Application
5.1 Global High Potency APIs (HPAPI) Historic Market Review by Application (2015-2020)
5.1.2 Global High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
5.1.3 Global High Potency APIs (HPAPI) Revenue Market Share by Application (2015-2020)
5.1.4 High Potency APIs (HPAPI) Price by Application (2015-2020)
5.2 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global High Potency APIs (HPAPI) Sales Forecast by Application (2021-2026)
5.2.3 Global High Potency APIs (HPAPI) Revenue Forecast by Application (2021-2026)
5.2.4 High Potency APIs (HPAPI) Price Forecast by Application (2021-2026)

6 North America
6.1 North America High Potency APIs (HPAPI) Breakdown Data by Company
6.2 North America High Potency APIs (HPAPI) Breakdown Data by Type
6.3 North America High Potency APIs (HPAPI) Breakdown Data by Application
6.4 North America High Potency APIs (HPAPI) Breakdown Data by Countries
6.4.1 North America High Potency APIs (HPAPI) Sales by Countries
6.4.2 North America High Potency APIs (HPAPI) Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe High Potency APIs (HPAPI) Breakdown Data by Company
7.2 Europe High Potency APIs (HPAPI) Breakdown Data by Type
7.3 Europe High Potency APIs (HPAPI) Breakdown Data by Application
7.4 Europe High Potency APIs (HPAPI) Breakdown Data by Countries
7.4.1 Europe High Potency APIs (HPAPI) Sales by Countries
7.4.2 Europe High Potency APIs (HPAPI) Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Company
8.2 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Type
8.3 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Application
8.4 Asia Pacific High Potency APIs (HPAPI) Breakdown Data by Regions
8.4.1 Asia Pacific High Potency APIs (HPAPI) Sales by Regions
8.4.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America High Potency APIs (HPAPI) Breakdown Data by Company
9.2 Latin America High Potency APIs (HPAPI) Breakdown Data by Type
9.3 Latin America High Potency APIs (HPAPI) Breakdown Data by Application
9.4 Latin America High Potency APIs (HPAPI) Breakdown Data by Countries
9.4.1 Latin America High Potency APIs (HPAPI) Sales by Countries
9.4.2 Latin America High Potency APIs (HPAPI) Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Type
10.2 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Application
10.3 Middle East and Africa High Potency APIs (HPAPI) Breakdown Data by Countries
10.3.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Countries
10.3.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Pfizer (US)
11.1.1 Pfizer (US) Corporation Information
11.1.2 Pfizer (US) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer (US) High Potency APIs (HPAPI) Products and Services
11.1.5 Pfizer (US) SWOT Analysis
11.1.6 Pfizer (US) Recent Developments
11.2 Novartis (Switzerland)
11.2.1 Novartis (Switzerland) Corporation Information
11.2.2 Novartis (Switzerland) Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Novartis (Switzerland) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Novartis (Switzerland) High Potency APIs (HPAPI) Products and Services
11.2.5 Novartis (Switzerland) SWOT Analysis
11.2.6 Novartis (Switzerland) Recent Developments
11.3 Sanofi (France)
11.3.1 Sanofi (France) Corporation Information
11.3.2 Sanofi (France) Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Sanofi (France) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Sanofi (France) High Potency APIs (HPAPI) Products and Services
11.3.5 Sanofi (France) SWOT Analysis
11.3.6 Sanofi (France) Recent Developments
11.4 Roche (Switzerland)
11.4.1 Roche (Switzerland) Corporation Information
11.4.2 Roche (Switzerland) Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Roche (Switzerland) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Roche (Switzerland) High Potency APIs (HPAPI) Products and Services
11.4.5 Roche (Switzerland) SWOT Analysis
11.4.6 Roche (Switzerland) Recent Developments
11.5 Eli Lilly and Company (US)
11.5.1 Eli Lilly and Company (US) Corporation Information
11.5.2 Eli Lilly and Company (US) Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly and Company (US) High Potency APIs (HPAPI) Products and Services
11.5.5 Eli Lilly and Company (US) SWOT Analysis
11.5.6 Eli Lilly and Company (US) Recent Developments
11.6 Merck (US)
11.6.1 Merck (US) Corporation Information
11.6.2 Merck (US) Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Merck (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Merck (US) High Potency APIs (HPAPI) Products and Services
11.6.5 Merck (US) SWOT Analysis
11.6.6 Merck (US) Recent Developments
11.7 AbbVie (US)
11.7.1 AbbVie (US) Corporation Information
11.7.2 AbbVie (US) Business Overview and Total Revenue (2019 VS 2018)
11.7.3 AbbVie (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 AbbVie (US) High Potency APIs (HPAPI) Products and Services
11.7.5 AbbVie (US) SWOT Analysis
11.7.6 AbbVie (US) Recent Developments
11.8 Boehringer Ingelheim (Germany)
11.8.1 Boehringer Ingelheim (Germany) Corporation Information
11.8.2 Boehringer Ingelheim (Germany) Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Products and Services
11.8.5 Boehringer Ingelheim (Germany) SWOT Analysis
11.8.6 Boehringer Ingelheim (Germany) Recent Developments
11.9 GlaxoSmithKline (UK)
11.9.1 GlaxoSmithKline (UK) Corporation Information
11.9.2 GlaxoSmithKline (UK) Business Overview and Total Revenue (2019 VS 2018)
11.9.3 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Products and Services
11.9.5 GlaxoSmithKline (UK) SWOT Analysis
11.9.6 GlaxoSmithKline (UK) Recent Developments
11.10 RAG-Stiftung (Germany)
11.10.1 RAG-Stiftung (Germany) Corporation Information
11.10.2 RAG-Stiftung (Germany) Business Overview and Total Revenue (2019 VS 2018)
11.10.3 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Products and Services
11.10.5 RAG-Stiftung (Germany) SWOT Analysis
11.10.6 RAG-Stiftung (Germany) Recent Developments
11.11 Bristol-Myers Squibb (US)
11.11.1 Bristol-Myers Squibb (US) Corporation Information
11.11.2 Bristol-Myers Squibb (US) Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Products and Services
11.11.5 Bristol-Myers Squibb (US) SWOT Analysis
11.11.6 Bristol-Myers Squibb (US) Recent Developments
11.12 Teva (Israel)
11.12.1 Teva (Israel) Corporation Information
11.12.2 Teva (Israel) Business Overview and Total Revenue (2019 VS 2018)
11.12.3 Teva (Israel) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 Teva (Israel) High Potency APIs (HPAPI) Products and Services
11.12.5 Teva (Israel) SWOT Analysis
11.12.6 Teva (Israel) Recent Developments
11.13 Mylan (US)
11.13.1 Mylan (US) Corporation Information
11.13.2 Mylan (US) Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Mylan (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Mylan (US) High Potency APIs (HPAPI) Products and Services
11.13.5 Mylan (US) SWOT Analysis
11.13.6 Mylan (US) Recent Developments
11.14 AstraZeneca (UK)
11.14.1 AstraZeneca (UK) Corporation Information
11.14.2 AstraZeneca (UK) Business Overview and Total Revenue (2019 VS 2018)
11.14.3 AstraZeneca (UK) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 AstraZeneca (UK) High Potency APIs (HPAPI) Products and Services
11.14.5 AstraZeneca (UK) SWOT Analysis
11.14.6 AstraZeneca (UK) Recent Developments
11.15 Lonza (Swiss)
11.15.1 Lonza (Swiss) Corporation Information
11.15.2 Lonza (Swiss) Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Lonza (Swiss) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Lonza (Swiss) High Potency APIs (HPAPI) Products and Services
11.15.5 Lonza (Swiss) SWOT Analysis
11.15.6 Lonza (Swiss) Recent Developments
11.16 Ash Stevens (US)
11.16.1 Ash Stevens (US) Corporation Information
11.16.2 Ash Stevens (US) Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Ash Stevens (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Ash Stevens (US) High Potency APIs (HPAPI) Products and Services
11.16.5 Ash Stevens (US) SWOT Analysis
11.16.6 Ash Stevens (US) Recent Developments
11.17 AMRI (US)
11.17.1 AMRI (US) Corporation Information
11.17.2 AMRI (US) Business Overview and Total Revenue (2019 VS 2018)
11.17.3 AMRI (US) High Potency APIs (HPAPI) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 AMRI (US) High Potency APIs (HPAPI) Products and Services
11.17.5 AMRI (US) SWOT Analysis
11.17.6 AMRI (US) Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 High Potency APIs (HPAPI) Sales Channels
12.2.2 High Potency APIs (HPAPI) Distributors
12.3 High Potency APIs (HPAPI) Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.1.1 Global High Potency APIs (HPAPI) Sales Forecast by Regions (2021-2026)
13.1.2 Global High Potency APIs (HPAPI) Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.2.2 North America High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.2.3 North America High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.3.2 Europe High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.3.3 Europe High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.4.2 Asia Pacific High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.4.3 Asia Pacific High Potency APIs (HPAPI) Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.5.2 Latin America High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.5.3 Latin America High Potency APIs (HPAPI) Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa High Potency APIs (HPAPI) Sales Forecast (2021-2026)
13.6.2 Middle East and Africa High Potency APIs (HPAPI) Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa High Potency APIs (HPAPI) Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Pfizer (US)、Novartis (Switzerland)、Sanofi (France)、Roche (Switzerland)、Eli Lilly and Company (US)、Merck (US)、AbbVie (US)、Boehringer Ingelheim (Germany)、GlaxoSmithKline (UK)、RAG-Stiftung (Germany)、Bristol-Myers Squibb (US)、Teva (Israel)、Mylan (US)、AstraZeneca (UK)、Lonza (Swiss)、Ash Stevens (US)、AMRI (US)

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 高効能API(HPAPI)の世界市場2020-2026:画期的、一般(Global High Potency APIs (HPAPI) Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。